5-碘-3-甲氧基-7-甲基-1,2-苯并恶唑 | 864756-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 中文名称: 5-碘-3-甲氧基-7-甲基-1,2-苯并恶唑
• 英文名称: 5-iodo-3-methoxy-7-methylbenzo[d]isoxazole
• 英文别名: 5-iodo-3-methoxy-7-methyl-1,2-benzoxazole
• CAS: 864756-01-4
• 化学式: C₉H₈INO₂
• 分子量: 289.073
• InChiKey: GOGINZFWDNHPTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-碘-3-甲氧基-7-甲基-1,2-苯并恶唑 、 S-methyl 2-methoxy-3-methyl-5-[5-(5-methyl-[1,3,4]oxadiazol-2-yl)pent-1-enyl]benzothioate 在 四(三苯基膦)钯 三正丁基氢锡 、 copper(l) iodide 、 cesium fluoride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以212 mg的产率得到(Z)-S-methyl 2-methoxy-5-(1-(3-methoxy-7-methylbenzo[d]isoxazol-5-yl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)pent-1-enyl)-3-methylbenzothioate
  参考文献：
  名称：

  具有增强的水解稳定性的烯基二芳基甲烷HIV-1非核苷逆转录酶抑制剂的合成和生物学评估。

  摘要：

  HIV逆转录酶（NNRTIs）的非核苷抑制剂尽管不是HIV / AIDS治疗的主要手段，但由于其独特的作用机理，在高活性抗逆转录病毒疗法（HAART）中已变得越来越重要。几年前，我们的研究小组将烯基二芳基甲烷（ADAMs）鉴定为一种有效的新型NNRTIs。然而，发现活性最高的化合物在代谢上不稳定。随后的工作通过用各种杂环，腈和硫代酯代替不稳定的酯，从而合成了33种具有改善的代谢特性的类似物。结果，在纳摩尔浓度范围内鉴定出许多具有抗HIV活性的水解稳定的NNRTI。此外，基于新的ADAM系列，开发了一种改进的药效团模型，

  DOI：

  10.1021/jm070382k
• 作为产物：
  描述：

  2,N-dihydroxy-5-iodo-3-methylbenzamide 在 potassium carbonate 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 26.0h， 生成 5-碘-3-甲氧基-7-甲基-1,2-苯并恶唑
  参考文献：
  名称：

  Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

  摘要：

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) are part of the combination therapy currently used to treat HIV infection. Based on analogy with known HIV-1 NNRT inhibitors, 18 novel alkenyldiarylmethanes (ADAMs) containing 5-chloro-2-methoxyphenyl, 3-eyanophenyl, or 3-fluoro-5-trifluoromethylphenyl groups were synthesized and evaluated as HIV inhibitors. Their stabilities in rat plasma have also been investigated. Although introducing 5-chloro-2-methoxyphenyl or 3-fluoro-5-trifluoromethylphenyl groups into alkenyldiarylmethanes does not maintain the antiviral potency, the structural modification of alkenyldiarylmethanes with a 3-cyanophenyl substituent can be made without a large decrease in activity. The oxazolidinonyl group was introduced into the alkenyldiarylmethane framework and found to confer enhanced metabolic stability in rat plasma.

  DOI：

  10.1021/jm050452s

文献信息

• Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof
  申请人：Cushman Mark S.

  公开号：US20080300288A1

  公开（公告）日：2008-12-04

  Non-nucleoside inhibitors of HIV-1 reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing Non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  HIV-1反转录酶的非核苷类抑制剂被描述。这些抑制剂可以作为治疗HIV感染的联合疗法的一部分使用。本文描述的化合物具有抗病毒效力。此外，本文描述的化合物具有代谢稳定性。本文还描述了制备HIV-1反转录酶非核苷类抑制剂的过程。
• ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY
  申请人：Purdue Research Foundation

  公开号：US20170267667A1

  公开（公告）日：2017-09-21

  The invention disclosed herein pertains to compounds of alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of patients with acquired-immune deficiency syndrome (AIDS). Also described are methods for treating AIDS patients using the described alkenyldiarylmethane compounds.

  本发明涉及烯烃二芳基甲烷（ADAMs）化合物作为非核苷类逆转录酶抑制剂（NNRTIs），用于治疗获得性免疫缺陷综合症（AIDS）患者。还描述了使用所述烯烃二芳基甲烷化合物治疗AIDS患者的方法。
• Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy
  作者：Ayako Hoshi、Takeshi Sakamoto、Jun Takayama、Meiyan Xuan、Mari Okazaki、Tracy L. Hartman、Robert W. Buckheit、Christophe Pannecouque、Mark Cushman

  DOI：10.1016/j.bmc.2016.05.010

  日期：2016.7

  ‘best’ one in terms of inhibitory activity versus HIV-1 reverse transcriptase (RT) led to the realization that the potencies are critically dependent on the surrounding structure at each location, and therefore the definition of universal rank order is impossible. This investigation produced several new non-nucleoside reverse transcriptase inhibitors in which all three of the three methyl esters of the

  烯基二芳基甲烷（ADAM）是一类针对HIV-1的非核苷类逆转录酶抑制剂（NNRTIs）。四个化学和代谢稳定的ADAM结合了N先前已经报道了先导化合物的甲酯的-甲氧基亚氨基卤化物的替代物。在这项研究中，合成了二十五个新的ADAM，以研究在三个不同的位置安装九个不同的甲酯生物异构体的生物学后果。尝试定义甲基酯生物异构体的普遍等级顺序，并发现其抑制活性相对于HIV-1逆转录酶（RT）的“最佳”水平，这使人们认识到，效力在很大程度上取决于每个位置的周围结构，因此，不可能定义通用等级顺序。这项研究产生了几种新的非核苷类逆转录酶抑制剂，其中先导化合物的三个甲基酯中的所有三个都被甲基酯生物等排体取代，
• Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors
  作者：Bo-Liang Deng、Yujie Zhao、Tracy L. Hartman、Karen Watson、Robert W. Buckheit Jr.、Christophe Pannecouque、Erik De Clercq、Mark Cushman

  DOI：10.1016/j.ejmech.2008.09.013

  日期：2009.3

  stable bioisosteres, compounds bearing benzo[d]isoxazole and oxazolidine-2-one rings were designed and evaluated as a new series of potent HIV-1 non-nucleoside reverse transcriptase inhibitors with anti-HIV activity. All of the resulting ADAMs were found to inhibit HIV-1 RT with poly(rC)·oligo(dG) as the template primer. The most promising compound in this series was ADAM 3, with EC50 values of 40 nM (vs

  为了继续用稳定的生物等排体取代链烯基二芳基碳酸铅的代谢不稳定的甲基酯（ADAM），设计了带有苯并[ d ]异恶唑和恶唑烷-2-酮环的化合物，并将其评估为一系列新的有效HIV-1非-具有抗HIV活性的核苷逆转录酶抑制剂。发现所有所得的ADAM均以poly（rC）·oligo（dG）为模板引物抑制HIV-1 RT。该系列中最有前途的化合物是ADAM 3，其EC 50值为40 nM（vs HIV-1 RF）和20 nM（vs HIV-1 IIIB）。化合物3还抑制HIV-1逆转录酶，IC 50为0.91μM。ADAM 4在CEM-SS细胞中具有0.6μM的抗病毒EC 50和51.4分钟的血浆半衰期。
• Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings
  作者：Bo-Liang Deng、Matthew D. Cullen、Zhigang Zhou、Tracy L. Hartman、Robert W. Buckheit、Christophe Pannecouque、Erik De Clercq、Phillip E. Fanwick、Mark Cushman

  DOI：10.1016/j.bmc.2005.11.014

  日期：2006.4

  The HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) constitute a large and structurally diverse set of compounds, several of which are currently used in the treatment of AIDS. A series of novel alkenyldiarylmethanes (ADAMs) were designed and synthesized as part of an ongoing investigation to replace the metabolically labile methyl ester moieties found in the ADAM pharmacophore with stable modifications that retain the potent anti-HIV activity of the parent compounds. Unsurprisingly, the rat plasma half-lives of the new ADAMs were not improved when compared to the parent compounds, but all of the synthesized ADAMs inhibited the cytopathic effect of HIV-1 in cell culture. The most potent compound identified was (E)-5-[1-(3,7-dimethyl-2oxo-2,3-dihydro-benzoxazol-5-yl)-5-methoxycarbonyl-pent-1-enyl]-2-methoxy-3-methylbenzoic acid methyl ester (7), which inhibited the cytopathic effects of both HIV-1(RF) and HIV-1(IIIB) strains in cell cultures with EC50 values of 30 and 90 nM, respectively, and inhibited HIV-1 reverse transcriptase with an IC50 of 20 nM. (c) 2005 Elsevier Ltd. All rights reserved.